2 Stocks to Buy With Dividends Yielding More Than 4%
These two triple-net-lease REITs offer safe and reliable yields to dividend investors at fair valuations.
2 Top Healthcare Stocks to Buy Right Now
Both of these stocks are healthcare leaders and they're trading at reasonable valuations.
2 Embarrassingly Cheap Dividend Stocks to Buy
The market has written off these two high-quality stocks, but both could complement an income investor's portfolio.
2 Best Biotech Stocks to Buy in September
The market's caution when it comes to the healthcare sector presents a buying opportunity for these two solid businesses.
2 Dividend Stocks That Will Pay You for Life
Are you looking for steady dividends to stand the test of time? Here are a couple of stocks to consider buying.
How Keytruda's Latest Approval in China Boosts Merck
Keytruda received its second regulatory approval in China for the treatment of esophageal cancer.
These Promising Clinical Results Could Be Huge for Amgen Investors
New data from the phase 3 trial of tezepelumab bodes well for the drug candidate becoming a significant revenue producer in the near future.
Could This Be Pfizer's Next Blockbuster Vaccine?
Pfizer isn't resting on the laurels of its COVID vaccine success.
Could This Game-Changing FDA Approval Mean Profit for Johnson & Johnson Shareholders?
Johnson & Johnson's Invega Hafyera was approved by the FDA as the first and only twice-yearly injectable treatment for schizophrenia.
Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?
The EC's approval of Rinvoq for moderate to severe eczema is another step in the right direction for the company.
Merck Investors Have Reason to Cheer This Label Expansion
The biopharma company announced that it received two more approved indications for Keytruda in Japan.
Williams-Sonoma Knows How to Treat Its Shareholders
This specialty retailer handed out its second dividend hike of the year and authorized a new, larger share repurchase program.
AstraZeneca Enters Another Major Market With This Indication
The pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan.
Is This Medical-Device-Making Dividend Aristocrat a Buy?
Medtronic met analysts' consensus revenue estimate and exceeded earnings forecasts in the first quarter of its fiscal 2022.
Is This Monthly Dividend Payer a Buy?
Realty Income is one of the steadiest publicly traded REITs, and growth should accelerate with record acquisitions set for this year.
Does the Pullback in This Pharma Stock Create a Buying Opportunity?
Amgen continues to face the headwind of patient visits that are lower than before the pandemic.
Here's What This Label Expansion Could Mean for Eli Lilly Investors
The pharmaceutical company's type 2 diabetes drug Jardiance was recently approved by the FDA for another indication.
Could These Clinical Results Mean Profit for AbbVie Shareholders?
The pharma stock announced strong phase 3 results for atogepant in the preventive treatment of episodic migraine.
This Potential Indication Could Mean Profit for Eli Lilly Investors
Eli Lilly updated investors on its ongoing phase 3 trials to treat patients who have moderate to severe eczema with a new drug.
Should You Buy the Dip in This Pet Insurer?
Trupanion reported a mixed second quarter with a revenue beat and an EPS miss.